|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2010-3-17
|
|
pubmed:abstractText |
Congestive heart failure (CHF) has been associated with elevated biomarker levels reflecting chronic low-grade inflammation. YKL-40 is a biomarker with increasing levels in patients with cardiovascular disease (CVD) of increasing severity. Furthermore, YKL-40 is associated with all-cause and cardiovascular mortality. We investigated plasma YKL-40 levels in patients with CHF and evaluated the possible predictive value with respect to overall mortality and recurrent cardiovascular outcomes.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adipokines,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/C-Reactive Protein,
http://linkedlifedata.com/resource/pubmed/chemical/CHI3L1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Creatinine,
http://linkedlifedata.com/resource/pubmed/chemical/E-Selectin,
http://linkedlifedata.com/resource/pubmed/chemical/Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Lectins,
http://linkedlifedata.com/resource/pubmed/chemical/Natriuretic Peptide, Brain,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/pro-brain natriuretic peptide (1-76),
http://linkedlifedata.com/resource/pubmed/chemical/von Willebrand Factor
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1651-2006
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
44
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
92-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19961288-Adipokines,
pubmed-meshheading:19961288-Aged,
pubmed-meshheading:19961288-Albuminuria,
pubmed-meshheading:19961288-Biological Markers,
pubmed-meshheading:19961288-C-Reactive Protein,
pubmed-meshheading:19961288-Case-Control Studies,
pubmed-meshheading:19961288-Chronic Disease,
pubmed-meshheading:19961288-Comorbidity,
pubmed-meshheading:19961288-Creatinine,
pubmed-meshheading:19961288-Denmark,
pubmed-meshheading:19961288-E-Selectin,
pubmed-meshheading:19961288-Female,
pubmed-meshheading:19961288-Glycoproteins,
pubmed-meshheading:19961288-Heart Failure,
pubmed-meshheading:19961288-Humans,
pubmed-meshheading:19961288-Lectins,
pubmed-meshheading:19961288-Linear Models,
pubmed-meshheading:19961288-Male,
pubmed-meshheading:19961288-Middle Aged,
pubmed-meshheading:19961288-Natriuretic Peptide, Brain,
pubmed-meshheading:19961288-Peptide Fragments,
pubmed-meshheading:19961288-Predictive Value of Tests,
pubmed-meshheading:19961288-Prognosis,
pubmed-meshheading:19961288-Proportional Hazards Models,
pubmed-meshheading:19961288-Risk Assessment,
pubmed-meshheading:19961288-Risk Factors,
pubmed-meshheading:19961288-Time Factors,
pubmed-meshheading:19961288-Up-Regulation,
pubmed-meshheading:19961288-von Willebrand Factor
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Plasma YKL-40 levels are elevated in patients with chronic heart failure.
|
|
pubmed:affiliation |
Department of Endocrinology, Copenhagen University Hospital Herlev, Denmark. cnr@dadlnet.dk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
